Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer

BJU International

Volumn 105, Issue 8, 2010, Pages 1082-1088

  Wadhwa, Vivek K ^a   Weston, Robin ^a   Parr, Nigel J ^a  

^a WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation therapy; Bisphosphonates; Osteoporosis; Prostate cancer; Zoledronic acid

Indexed keywords

ANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; GONADORELIN AGONIST; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; THORACOLUMBAR SPINE; VERTEBRA FRACTURE;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NITRILES; OSTEOPOROSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 77950220451     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08956.x     Document Type: Article

References (30)

1. Cooperberg MR, Grossfeld GD, Lubeck DP et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003 95 : 981 989
2. Chang SS. Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer. Urology 2003 62 (Suppl. 6A 29 35
3. Daniell HW. Osteoporosis after orchidectomy for prostate cancer. J Urol 1997 157 : 439 444
4. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 164
5. Oefelein MG, Ricchiuti V, Conrad W et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002 168 : 1005 1007
6. Hussain SA, Weston R, Stephenson RN et al. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003 92 : 690 694
7. Sieber PR, Keiller DL, Kahnoski RJ et al. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localised or locally advanced prostate cancer. J Urol 2004 171 : 2272 2276
8. Iversen P, Tyrrell CJ, Kaisary AV et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000 164 : 1579 1582
9. Heidenrich A, Bolla M, Joniau S et al. European Association of Urology Guidelines. Prostate Cancer 2009 12 : 80
10. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 346 : 653 661
11. Smith MR, Eastham J, Gleason DM et al. Randomised controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003 169 : 2008 2012
12. Ryan CW, Huo D, Demers LM et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006 176 : 972 978
13. Israeli RS, Rosenberg SJ, Saltzstein DR et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007 5 : 271 277
14. Michaelson MD, Kaufman DS, Lee H et al. Randomised controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007 25 : 1038 1042
15. Verhelst J, Denis L, Van Vliet P et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrin 1994 41 : 525 530
16. Slemenda CW, Longcope C, Zhou L et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997 100 : 1755 1759
17. Weston R, Hussain A, George E et al. Testosterone recovery and changes in bone mineral density after stopping long- term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer. BJU Int 2005 95 : 776 779
18. Melton LJ Atkinson EJ, O'Connor MK et al. Bone density and fracture risk in men. J Bone Miner Res 1998 13 : 1915 1923
19. Mole PA, McMuro MET, Paterson CR. Evaluation of peripheral dual energy X-ray absorptiometry: comparison with single photon absorptiometry of the forearm and dual energy X-ray absorptiometry of the spine or femur. Br J Radiol 1998 71 : 427 432
20. Greenspan S, Nelson JB, Trump DL et al. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med 2007 146 : 416 424
21. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001 345 : 948 955
22. Wadhwa VK, Weston R, Mistry R et al. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. BJU Int 2009 104 : 800 805
23. Van Daele PL, Seibel MJ, Burger H et al. Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 1996 312 : 482 483
24. Smith MR, Fallon MA, Goode M. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 2003 61 : 127 131
25. Fleisch H. Bisphosphonates in Bone Disease: from the laboratory to the patient. New York : The Parthenon Publishing Group, 1995 : 40 1
26. De Lacet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998 13 : 1587 1593
27. López AM, Pena MA, Hernández R. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 2005 16 : 707 711
28. Green JR. Antitumour effects of bisphosphonates. Cancer 2003 97 : 840 847
29. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003 349 : 1676 1679
30. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003 61 : 1115 1117